Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour

Ferdinando C M Cananzi, Ajay P. Belgaumkar, Bruno Lorenzi, Satvinder Mudan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: After the introduction of tyrosine kinase inhibitors (TKIs), the role of surgical resection in treating liver metastasis from gastrointestinal stromal tumour (GIST) is unclear. In this study, we evaluated the outcome of patients treated with TKIs followed by surgery for metastatic GIST. Methods: Eleven patients underwent liver resection after downsizing TKIs therapy for metastatic GIST from 2006 until 2010 were reviewed. Results: One and two-year overall survival rates were 80.8 and 70.7%. All patients with an initially resectable tumour were still alive without recurrence. Patients operated on clinical response had a better outcome (1- and 2-year overall survival (OS) rate 100%) than those operated on disease progression (1- and 2-year OS rates 60 and 40%; P=0.043). No deaths were observed among patients who achieved an R0 resection (R0 versus R1/R2, P=0.001). Discussion: R0 resection and clinical response to TKI are predictor of survival. Surgical resection should be performed as soon as feasible in responding patients. In poor responders, surgery may not add any survival benefit, except in localized progressive disease. In resectable metastatic liver disease, preoperative TKIs or upfront surgery followed by adjuvant therapy could be considered. Larger studies are needed to determine the optimum approach in patients with metastatic GIST.

Original languageEnglish
Pages (from-to)E1-E8
JournalANZ Journal of Surgery
Volume84
Issue number12
DOIs
Publication statusPublished - 2014

Fingerprint

Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Liver
Survival Rate
Survival
Disease Progression
Liver Diseases
Neoplasm Metastasis
Recurrence
Therapeutics

Keywords

  • GIST
  • Imatinib
  • Liver metastases
  • Liver resection
  • Preoperative therapy

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour. / Cananzi, Ferdinando C M; Belgaumkar, Ajay P.; Lorenzi, Bruno; Mudan, Satvinder.

In: ANZ Journal of Surgery, Vol. 84, No. 12, 2014, p. E1-E8.

Research output: Contribution to journalArticle

Cananzi, Ferdinando C M ; Belgaumkar, Ajay P. ; Lorenzi, Bruno ; Mudan, Satvinder. / Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour. In: ANZ Journal of Surgery. 2014 ; Vol. 84, No. 12. pp. E1-E8.
@article{caf52dcca0894453877503d30ddc4286,
title = "Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour",
abstract = "Introduction: After the introduction of tyrosine kinase inhibitors (TKIs), the role of surgical resection in treating liver metastasis from gastrointestinal stromal tumour (GIST) is unclear. In this study, we evaluated the outcome of patients treated with TKIs followed by surgery for metastatic GIST. Methods: Eleven patients underwent liver resection after downsizing TKIs therapy for metastatic GIST from 2006 until 2010 were reviewed. Results: One and two-year overall survival rates were 80.8 and 70.7{\%}. All patients with an initially resectable tumour were still alive without recurrence. Patients operated on clinical response had a better outcome (1- and 2-year overall survival (OS) rate 100{\%}) than those operated on disease progression (1- and 2-year OS rates 60 and 40{\%}; P=0.043). No deaths were observed among patients who achieved an R0 resection (R0 versus R1/R2, P=0.001). Discussion: R0 resection and clinical response to TKI are predictor of survival. Surgical resection should be performed as soon as feasible in responding patients. In poor responders, surgery may not add any survival benefit, except in localized progressive disease. In resectable metastatic liver disease, preoperative TKIs or upfront surgery followed by adjuvant therapy could be considered. Larger studies are needed to determine the optimum approach in patients with metastatic GIST.",
keywords = "GIST, Imatinib, Liver metastases, Liver resection, Preoperative therapy",
author = "Cananzi, {Ferdinando C M} and Belgaumkar, {Ajay P.} and Bruno Lorenzi and Satvinder Mudan",
year = "2014",
doi = "10.1111/ans.12195",
language = "English",
volume = "84",
pages = "E1--E8",
journal = "ANZ Journal of Surgery",
issn = "1445-1433",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour

AU - Cananzi, Ferdinando C M

AU - Belgaumkar, Ajay P.

AU - Lorenzi, Bruno

AU - Mudan, Satvinder

PY - 2014

Y1 - 2014

N2 - Introduction: After the introduction of tyrosine kinase inhibitors (TKIs), the role of surgical resection in treating liver metastasis from gastrointestinal stromal tumour (GIST) is unclear. In this study, we evaluated the outcome of patients treated with TKIs followed by surgery for metastatic GIST. Methods: Eleven patients underwent liver resection after downsizing TKIs therapy for metastatic GIST from 2006 until 2010 were reviewed. Results: One and two-year overall survival rates were 80.8 and 70.7%. All patients with an initially resectable tumour were still alive without recurrence. Patients operated on clinical response had a better outcome (1- and 2-year overall survival (OS) rate 100%) than those operated on disease progression (1- and 2-year OS rates 60 and 40%; P=0.043). No deaths were observed among patients who achieved an R0 resection (R0 versus R1/R2, P=0.001). Discussion: R0 resection and clinical response to TKI are predictor of survival. Surgical resection should be performed as soon as feasible in responding patients. In poor responders, surgery may not add any survival benefit, except in localized progressive disease. In resectable metastatic liver disease, preoperative TKIs or upfront surgery followed by adjuvant therapy could be considered. Larger studies are needed to determine the optimum approach in patients with metastatic GIST.

AB - Introduction: After the introduction of tyrosine kinase inhibitors (TKIs), the role of surgical resection in treating liver metastasis from gastrointestinal stromal tumour (GIST) is unclear. In this study, we evaluated the outcome of patients treated with TKIs followed by surgery for metastatic GIST. Methods: Eleven patients underwent liver resection after downsizing TKIs therapy for metastatic GIST from 2006 until 2010 were reviewed. Results: One and two-year overall survival rates were 80.8 and 70.7%. All patients with an initially resectable tumour were still alive without recurrence. Patients operated on clinical response had a better outcome (1- and 2-year overall survival (OS) rate 100%) than those operated on disease progression (1- and 2-year OS rates 60 and 40%; P=0.043). No deaths were observed among patients who achieved an R0 resection (R0 versus R1/R2, P=0.001). Discussion: R0 resection and clinical response to TKI are predictor of survival. Surgical resection should be performed as soon as feasible in responding patients. In poor responders, surgery may not add any survival benefit, except in localized progressive disease. In resectable metastatic liver disease, preoperative TKIs or upfront surgery followed by adjuvant therapy could be considered. Larger studies are needed to determine the optimum approach in patients with metastatic GIST.

KW - GIST

KW - Imatinib

KW - Liver metastases

KW - Liver resection

KW - Preoperative therapy

UR - http://www.scopus.com/inward/record.url?scp=84925855413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925855413&partnerID=8YFLogxK

U2 - 10.1111/ans.12195

DO - 10.1111/ans.12195

M3 - Article

C2 - 23647808

AN - SCOPUS:84925855413

VL - 84

SP - E1-E8

JO - ANZ Journal of Surgery

JF - ANZ Journal of Surgery

SN - 1445-1433

IS - 12

ER -